PYXIS ONCOLOGY INC (PYXS)
US7473241013 - Common Stock
PYXS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. The financial health of PYXS is average, but there are quite some concerns on its profitability. PYXS does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year PYXS has reported negative net income.
PYXS had a negative operating cash flow in the past year.
In the past 5 years PYXS always reported negative net income.
In the past 5 years PYXS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -29.37%, PYXS is in the better half of the industry, outperforming 69.91% of the companies in the same industry.
With a decent Return On Equity value of -37.32%, PYXS is doing good in the industry, outperforming 73.98% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.37% | ||
| ROE | -37.32% | ||
| ROIC | N/A |
ROA(3y)-42.24%
ROA(5y)-53.3%
ROE(3y)-54.28%
ROE(5y)-76.2%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PYXS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for PYXS has been increased compared to 1 year ago.
There is no outstanding debt for PYXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PYXS has an Altman-Z score of -1.38. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
PYXS has a Altman-Z score (-1.38) which is comparable to the rest of the industry.
PYXS has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
PYXS has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: PYXS outperforms 48.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.38 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
PYXS has a Current Ratio of 7.33. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
PYXS has a Current ratio of 7.33. This is in the better half of the industry: PYXS outperforms 69.20% of its industry peers.
A Quick Ratio of 7.33 indicates that PYXS has no problem at all paying its short term obligations.
PYXS has a better Quick ratio (7.33) than 69.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.33 | ||
| Quick Ratio | 7.33 |
3. Growth
3.1 Past
PYXS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 59.29%, which is quite impressive.
EPS 1Y (TTM)59.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, PYXS will show a small growth in Earnings Per Share. The EPS will grow by 3.90% on average per year.
Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 168.63% on average per year.
EPS Next Y40.06%
EPS Next 2Y15.38%
EPS Next 3Y9.53%
EPS Next 5Y3.9%
Revenue Next Year8174.54%
Revenue Next 2Y-41.42%
Revenue Next 3Y192.4%
Revenue Next 5Y168.64%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PYXS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYXS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.38%
EPS Next 3Y9.53%
5. Dividend
5.1 Amount
No dividends for PYXS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PYXIS ONCOLOGY INC
NASDAQ:PYXS (1/14/2025, 8:01:18 PM)
Premarket: 1.44 0 (0%)1.44
-0.09 (-5.88%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners55%
Inst Owner Change-0.01%
Ins Owners7.66%
Ins Owner Change0%
Market Cap85.64M
Analysts85.71
Price Target10.05 (597.92%)
Short Float %16.75%
Short Ratio5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.41%
Min EPS beat(2)-9.51%
Max EPS beat(2)12.33%
EPS beat(4)3
Avg EPS beat(4)27.6%
Min EPS beat(4)-9.51%
Max EPS beat(4)75.69%
EPS beat(8)5
Avg EPS beat(8)21.67%
EPS beat(12)5
Avg EPS beat(12)-26.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.48%
PT rev (3m)7.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-21.23%
EPS NY rev (1m)0.72%
EPS NY rev (3m)-4.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)2.68%
Revenue NY rev (3m)7.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.3 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.56 | ||
| P/tB | 0.66 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.03
EYN/A
EPS(NY)-1.24
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.9
OCFYN/A
SpS0.27
BVpS2.58
TBVpS2.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -29.37% | ||
| ROE | -37.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-42.24%
ROA(5y)-53.3%
ROE(3y)-54.28%
ROE(5y)-76.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.08
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 7.47% | ||
| Cap/Sales | 1.44% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.33 | ||
| Quick Ratio | 7.33 | ||
| Altman-Z | -1.38 |
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)444.51%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)59.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y40.06%
EPS Next 2Y15.38%
EPS Next 3Y9.53%
EPS Next 5Y3.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year8174.54%
Revenue Next 2Y-41.42%
Revenue Next 3Y192.4%
Revenue Next 5Y168.64%
EBIT growth 1Y34.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-65.18%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.24%
OCF growth 3YN/A
OCF growth 5YN/A